A detailed history of Profund Advisors LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 8,807 shares of MDGL stock, worth $3.04 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
8,807
Previous 6,816 29.21%
Holding current value
$3.04 Million
Previous $1.91 Million 2.1%
% of portfolio
0.07%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$212.22 - $292.96 $422,530 - $583,283
1,991 Added 29.21%
8,807 $1.87 Million
Q2 2024

Aug 13, 2024

BUY
$193.33 - $291.99 $203,576 - $307,465
1,053 Added 18.27%
6,816 $1.91 Million
Q1 2024

May 08, 2024

SELL
$171.37 - $283.23 $239,403 - $395,672
-1,397 Reduced 19.51%
5,763 $1.54 Million
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $67,785 - $133,504
-563 Reduced 7.29%
7,160 $1.66 Million
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $277,183 - $428,530
1,898 Added 32.58%
7,723 $1.13 Million
Q2 2023

Aug 10, 2023

BUY
$203.88 - $312.0 $93,580 - $143,208
459 Added 8.55%
5,825 $1.35 Million
Q1 2023

May 11, 2023

BUY
$231.06 - $307.08 $978,076 - $1.3 Million
4,233 Added 373.61%
5,366 $1.3 Million
Q4 2022

Feb 02, 2023

BUY
$58.39 - $296.54 $66,155 - $335,979
1,133 New
1,133 $328,000
Q1 2019

May 15, 2019

SELL
$103.48 - $143.84 $189,264 - $263,083
-1,829 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$94.77 - $215.54 $6,349 - $14,441
67 Added 3.8%
1,829 $206,000
Q3 2018

Nov 13, 2018

BUY
$207.3 - $300.31 $365,262 - $529,146
1,762 New
1,762 $377,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.9B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.